Precision Oncology: A Global Perspective on Implementation and Policy Development
Despite the acknowledged merits of precision oncology (PO) and its increasing global implementation, its full potential for advancing care and prevention remains unrealized. The benefits are currently accessible to only limited patient segments because of multifaceted barriers. Successful implementa...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
American Society of Clinical Oncology
2025-04-01
|
| Series: | JCO Global Oncology |
| Online Access: | https://ascopubs.org/doi/10.1200/GO-24-00416 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849761019293859840 |
|---|---|
| author | Denis Horgan Marcel Tanner Charu Aggarwal David Thomas Surbhi Grover Lina Basel-Salmon Rodrigo Dienstmann Tira Jing Ying Tan Woong-Yang Park Hadi Mohamad Abu Rasheed Lillian L. Siu Brigette Ma Rocío Ortiz-López Marc Van den Bulcke Silvia Castillo Taucher Andrea Ferris Naureen Starling Umberto Malapelle John Longshore Hugo Alberto Barrera Saldaña Vivek Subbiah |
| author_facet | Denis Horgan Marcel Tanner Charu Aggarwal David Thomas Surbhi Grover Lina Basel-Salmon Rodrigo Dienstmann Tira Jing Ying Tan Woong-Yang Park Hadi Mohamad Abu Rasheed Lillian L. Siu Brigette Ma Rocío Ortiz-López Marc Van den Bulcke Silvia Castillo Taucher Andrea Ferris Naureen Starling Umberto Malapelle John Longshore Hugo Alberto Barrera Saldaña Vivek Subbiah |
| author_sort | Denis Horgan |
| collection | DOAJ |
| description | Despite the acknowledged merits of precision oncology (PO) and its increasing global implementation, its full potential for advancing care and prevention remains unrealized. The benefits are currently accessible to only limited patient segments because of multifaceted barriers. Successful implementation hinges on various factors—scientific complexities not limited to technical, clinical, regulatory, economic, administrative, and health care policy–related challenges. From building infrastructure to the associated costs, including research and development, testing, processing, and trained personnel, a lack of alignment persists. Administrative alignment with regulatory and payor acceptance is crucial. Health care policy must adapt to the ongoing shift from a one-size-fits-all treatment to a personalized approach. Without official endorsement of long-term gains over short-term costs and the health establishment's readiness for innovation, PO prospects, even in prosperous economies, may stagnate. Lower-income countries face exacerbated challenges, intensifying barriers to adoption. Nevertheless, growing awareness and utilization, driven by recognized potential for patients and public health, along with successful examples and advocacy, are progressively influencing policy for a more inclusive and beneficial approach to PO adoption. |
| format | Article |
| id | doaj-art-3c6fe1501b43442f9cc5555e4fa7f39f |
| institution | DOAJ |
| issn | 2687-8941 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | American Society of Clinical Oncology |
| record_format | Article |
| series | JCO Global Oncology |
| spelling | doaj-art-3c6fe1501b43442f9cc5555e4fa7f39f2025-08-20T03:06:09ZengAmerican Society of Clinical OncologyJCO Global Oncology2687-89412025-04-011110.1200/GO-24-00416Precision Oncology: A Global Perspective on Implementation and Policy DevelopmentDenis Horgan0Marcel Tanner1Charu Aggarwal2David Thomas3Surbhi Grover4Lina Basel-Salmon5Rodrigo Dienstmann6Tira Jing Ying Tan7Woong-Yang Park8Hadi Mohamad Abu Rasheed9Lillian L. Siu10Brigette Ma11Rocío Ortiz-López12Marc Van den Bulcke13Silvia Castillo Taucher14Andrea Ferris15Naureen Starling16Umberto Malapelle17John Longshore18Hugo Alberto Barrera Saldaña19Vivek Subbiah20European Alliance for Personalised Medicine, Brussels, BelgiumInternational Cancer Patient Coalition, Brussels, BelgiumDivision of Hematology-Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PACentre for Molecular Oncology, University of New South Wales, Sydney, AustraliaDepartment of Radiation Oncology, Hospital of University of Pennsylvania, Philadelphia, PARapahel Recanati Genetics Institute, Beilinson Hospital, Rabin Medical Center, Petach Tikva, IsraelOncology Data Science, Vall d'Hebron Institute of Oncology, Barcelona, SpainDivision of Medical Oncology, National Cancer Centre Singapore, Singapore, SingaporeSamsung Genome Institute, Samsung Medical Center, Seoul, KoreaQatar Cancer Society, Doha, QatarDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, CanadaDepartment of Clinical Oncology, Prince of Wales Hospital, State Key Laboratory in Oncology in South China, Chinese University of Hong Kong, Shatin, Hong KongSciensano, Brussels, BelgiumSchool of Medicine, Tecnologico de Monterrey, Monterrey, MexicoSección Citogenética, Laboratorio Clínico, Clínica Alemana de Santiago, Santiago, ChileHIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MDDepartment of Medicine, Royal Marsden Hospital, London, United KingdomDepartment of Public Health, University Federico II of Naples, Naples, ItalyAstraZeneca, Wilmington, DEUniversidad Autónoma de Nuevo León, Facultades de Medicina y Ciencias Bilógicas, San Nicolás de los Garza, MéxicoInternational Cancer Patient Coalition, Brussels, BelgiumDespite the acknowledged merits of precision oncology (PO) and its increasing global implementation, its full potential for advancing care and prevention remains unrealized. The benefits are currently accessible to only limited patient segments because of multifaceted barriers. Successful implementation hinges on various factors—scientific complexities not limited to technical, clinical, regulatory, economic, administrative, and health care policy–related challenges. From building infrastructure to the associated costs, including research and development, testing, processing, and trained personnel, a lack of alignment persists. Administrative alignment with regulatory and payor acceptance is crucial. Health care policy must adapt to the ongoing shift from a one-size-fits-all treatment to a personalized approach. Without official endorsement of long-term gains over short-term costs and the health establishment's readiness for innovation, PO prospects, even in prosperous economies, may stagnate. Lower-income countries face exacerbated challenges, intensifying barriers to adoption. Nevertheless, growing awareness and utilization, driven by recognized potential for patients and public health, along with successful examples and advocacy, are progressively influencing policy for a more inclusive and beneficial approach to PO adoption.https://ascopubs.org/doi/10.1200/GO-24-00416 |
| spellingShingle | Denis Horgan Marcel Tanner Charu Aggarwal David Thomas Surbhi Grover Lina Basel-Salmon Rodrigo Dienstmann Tira Jing Ying Tan Woong-Yang Park Hadi Mohamad Abu Rasheed Lillian L. Siu Brigette Ma Rocío Ortiz-López Marc Van den Bulcke Silvia Castillo Taucher Andrea Ferris Naureen Starling Umberto Malapelle John Longshore Hugo Alberto Barrera Saldaña Vivek Subbiah Precision Oncology: A Global Perspective on Implementation and Policy Development JCO Global Oncology |
| title | Precision Oncology: A Global Perspective on Implementation and Policy Development |
| title_full | Precision Oncology: A Global Perspective on Implementation and Policy Development |
| title_fullStr | Precision Oncology: A Global Perspective on Implementation and Policy Development |
| title_full_unstemmed | Precision Oncology: A Global Perspective on Implementation and Policy Development |
| title_short | Precision Oncology: A Global Perspective on Implementation and Policy Development |
| title_sort | precision oncology a global perspective on implementation and policy development |
| url | https://ascopubs.org/doi/10.1200/GO-24-00416 |
| work_keys_str_mv | AT denishorgan precisiononcologyaglobalperspectiveonimplementationandpolicydevelopment AT marceltanner precisiononcologyaglobalperspectiveonimplementationandpolicydevelopment AT charuaggarwal precisiononcologyaglobalperspectiveonimplementationandpolicydevelopment AT davidthomas precisiononcologyaglobalperspectiveonimplementationandpolicydevelopment AT surbhigrover precisiononcologyaglobalperspectiveonimplementationandpolicydevelopment AT linabaselsalmon precisiononcologyaglobalperspectiveonimplementationandpolicydevelopment AT rodrigodienstmann precisiononcologyaglobalperspectiveonimplementationandpolicydevelopment AT tirajingyingtan precisiononcologyaglobalperspectiveonimplementationandpolicydevelopment AT woongyangpark precisiononcologyaglobalperspectiveonimplementationandpolicydevelopment AT hadimohamadaburasheed precisiononcologyaglobalperspectiveonimplementationandpolicydevelopment AT lillianlsiu precisiononcologyaglobalperspectiveonimplementationandpolicydevelopment AT brigettema precisiononcologyaglobalperspectiveonimplementationandpolicydevelopment AT rocioortizlopez precisiononcologyaglobalperspectiveonimplementationandpolicydevelopment AT marcvandenbulcke precisiononcologyaglobalperspectiveonimplementationandpolicydevelopment AT silviacastillotaucher precisiononcologyaglobalperspectiveonimplementationandpolicydevelopment AT andreaferris precisiononcologyaglobalperspectiveonimplementationandpolicydevelopment AT naureenstarling precisiononcologyaglobalperspectiveonimplementationandpolicydevelopment AT umbertomalapelle precisiononcologyaglobalperspectiveonimplementationandpolicydevelopment AT johnlongshore precisiononcologyaglobalperspectiveonimplementationandpolicydevelopment AT hugoalbertobarrerasaldana precisiononcologyaglobalperspectiveonimplementationandpolicydevelopment AT viveksubbiah precisiononcologyaglobalperspectiveonimplementationandpolicydevelopment |